Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

丙戊酸 组蛋白脱乙酰酶抑制剂 药理学 组蛋白脱乙酰基酶 医学 表阿霉素 伏立诺他 内科学 癌症 化学 组蛋白 癫痫 生物化学 乳腺癌 基因 精神科
作者
Pamela N. Münster,Douglas C. Marchion,Elona Biçaku,Mira Lacevic,Jongphil Kim,Barbara Ann Centeno,ADIL I. DAUD,Anthony M. Neuger,Susan E. Minton,Daniel M. Sullivan
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:15 (7): 2488-2496 被引量:150
标识
DOI:10.1158/1078-0432.ccr-08-1930
摘要

PURPOSE: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. EXPERIMENTAL DESIGN: A phase I dose escalation of valproic acid given on days 1 to 3 followed by epirubicin (day 3) was followed by a dose expansion of valproic acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC100). Pharmacodynamic and pharmacokinetic studies entailed valproic acid and epirubicin plasma levels and their interaction, the effects of valproic acid on histone acetylation in peripheral blood mononuclear cells (PBMC) and tumor cells at baseline and day 3, and baseline expression of HDAC2 and HDAC6 as therapeutic targets. RESULTS: Forty-four patients were enrolled in the phase I part, with a disease-specific cohort expansion of 15 breast cancer patients (median age, 55 years; range, 28-66 years) receiving 120 mg/kg/day valproic acid followed by FEC100. Partial responses were seen in 9 of 41 (22%) patients during the phase I part. Objective responses were seen in 9 of 14 (64%) evaluable patients at the dose expansion with a median number of 6 administered cycles. Predominant toxicities were valproic acid-associated somnolence and epirubicin-induced myelosuppression. Valproic acid plasma levels were associated with short-term, reversible depletion of WBC and neutrophils within 48 hours. Histone acetylation in tumor samples and in PBMCs correlated with valproic acid levels and was further linked to baseline HDAC2 but not to HDAC6 expression. CONCLUSION: Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies. HDAC2 should be further considered as a relevant therapeutic target.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
观澜完成签到 ,获得积分10
刚刚
旺旺小福星完成签到 ,获得积分10
1秒前
文艺点点完成签到,获得积分10
1秒前
机智的香菇完成签到,获得积分10
1秒前
chuangLiu发布了新的文献求助10
2秒前
2秒前
3秒前
4秒前
chenqj发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
Caius完成签到 ,获得积分10
6秒前
Sci666完成签到 ,获得积分10
7秒前
yaro完成签到,获得积分10
7秒前
8秒前
流萤完成签到,获得积分10
8秒前
8秒前
阿白发布了新的文献求助10
9秒前
9秒前
mrjohn发布了新的文献求助10
9秒前
orixero的应助被苏邑采纳,获得10
9秒前
flexiblemonkeys完成签到,获得积分10
10秒前
风吹麦浪的应助被名古邬采纳,获得20
11秒前
orixero的应助被Rainvin采纳,获得10
12秒前
自信的牛排完成签到 ,获得积分10
12秒前
fdyy1完成签到,获得积分10
13秒前
漫漫发布了新的文献求助10
13秒前
姜OMG发布了新的文献求助10
13秒前
cgliuhx发布了新的文献求助10
13秒前
QQ发布了新的文献求助10
13秒前
小小发布了新的文献求助10
14秒前
Dee完成签到,获得积分10
14秒前
所所的应助被Re采纳,获得10
14秒前
啊啊啊完成签到,获得积分10
14秒前
麦当劳没有Creazy4完成签到,获得积分10
15秒前
16秒前
16秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527